US specialists have made progress in developing a revolutionary drug for diabetics that will eliminate the need for insulin injection.
Many medicines, especially proteins made from proteins, cannot be consumed by mouth because they are broken down into the oesophagus and to no avail.
Insulin is an example of how diabetic patients need to be injected daily or frequently, but experts at North Carolina University and the Massachusetts Institute of Technology have developed a smart insulin delivery device, which will help patients in the near future. Will monitor and provide medication if needed.
This device, such as an adhesive bandage, can be used once a day.
In the research published in the journal Nature Biomedical Engineering, the device's experiments were successful in mice and pigs, and scientists are now applying to the US-based FDA for permission to test its humans.
Its first successful experiments were performed on mice in 2015 and according to researchers our main goal is to help improve the health and quality of life of diabetic patients, this device will eliminate the need to constantly check blood sugar and Insulin will be injected when needed, it will mimic pancreatic functions and is very easy to use.
The device will load insulin in small needles smaller than one milligram, which will lower the blood's blood sugar level to the body at a certain level.
When blood sugar levels return to normal, the device will slow down the supply of insulin, and researchers say that it will reduce the risk of ingesting high amounts of insulin into the body, which causes various problems.
Diabetes patients have to know the glucose level by placing a droplet of blood on the device while insulin is injected into the body.
The coating of the polymer in the needles in this device so that it can survive in the gastric acid environment, the needle is smaller than the usual needle bleeding and does not need to be deepened.
Each needle enters the body about half a millimetre long enough for insulin delivery.
The technology was adopted by the FDA's Emerging Technology Program, which will support its approval process, and human trials are likely to begin in the next few years.